CYTOF — Altamira Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering
Brief: Altamira Therapeutics Says Streamlining Corporate Structure
Brief: Altamira Therapeutics Files For Resale Of Up To 2 Mln Shares By Selling Shareholder
Brief: Altamira Therapeutics, Univercells Group Partner On Nanoparticle-Delivered mRNA Vaccines
Brief: Altamira Therapeutics Files Second Provisional Patent Application For Oligophore Nanoparticles Targeting Different Kras Mutations In Cancer Treatment
Brief: Altamira Therapeutics Says Co Entered Into An At Market Offering Agreement
Brief: Altamira Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Altamira Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement
Brief: Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
Brief: Altamira Therapeutics Reports Additional Significant Efficacy Outcomes From Bentrio Clinical Trial In Seasonal Allergic Rhinitis
Brief: Altamira Therapeutics, Pharma Nordic Collaborate For Marketing And Distribution Of Bentrio In Scandinavia
Brief: Altamira Therapeutics Announces Collaboration With Heqet Therapeutics On Nanoparticle-Delivered Non-Coding RNAs For Cardiac Regeneration
Brief: Altamira Therapeutics Prospectus Relates To Disposition Of Up To 5.9 Mln Shares
Brief: Altamira Therapeutics Files Prospectus Relates To Resale Of Up To 2.5 Mln Shares By Lincoln Park Capital Fund
Brief: Altamira Therapeutics’ Semaphore Delivery Platform Shows Significant Synergis-Tic Effects Of Zbtb46 Mrna With Pd1 Immunotherapy In Control Of Tumor Growth In Animal Model
Brief: Altamira Therapeutics Ltd Files For Offering 3.2 Mln Of Common Shares - SEC Filing